# Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

> **NCT01516840** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 60 (actual)

## Conditions studied

- Deep Vein Thrombosis

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Unfractionated heparin
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT01516840
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516840, "Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01516840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*